Table 3.
Characteristics of all patients
| Total (n = 6,649) | E group (n = 2,357) | V group (n = 4,292) | p value | |
|---|---|---|---|---|
| Age, years | 69.4 (9.9) | 69.0 (10.2) | 69.6 (9.8) | 0.028 |
| Gender, M/F | 4,648/2,001 | 1,675/682 | 2,973/1,319 | 0.116 |
| HCV/HBV/HBV & HCV/Alc/nonBnonC/UK | 4,162/818/45/387/1,235/2 | 1,542/260/22/205/327/1 | 2,620/558/23/182/908/1 | <0.001 |
| Child-Pugh class, A/B/C | 4,812/1,546/291 | 1,713/567/77 | 3,099/979/214 | 0.422 |
| ALBI grade, 1/2/3 | 2,531/3,630/488 | 917/1,256/184 | 1,614/2,374/304 | 0.563 |
| mALBI grade, 1/2a/2b/3 | 4,162/818/45/387/1,235/2 | 917/518/738/184 | 1,614/934/1,440/304 | 0.348 |
| Tumor size, cm | 3.6 (3.1) | 3.5 (2.9) | 3.7 (3.2) | 0.012 |
| Tumor number, single/multiple | 3,934/2,715 | 1,438/919 | 2,496/1,796 | 0.024 |
| TNM stage, I/II/III/IV | 1,690/2,687/1416/856 | 601/995/479/282 | 1,089/1,692/937/574 | 0.093 |
| JIS score, 0/1/2/3/4/5 | 1,337/2,364/1,581/886/374/107 | 469/873/570/302/114/29 | 868/1491/1011/584/260/78 | 0.101 |
| ALBI-T score, 0/1/2/3/4/5 | 721/2,064/1,897/1,188/624/155 | 260/762/665/400/219/51 | 461/1,302/1232/788/405/104 | 0.087 |
| mALBI-T score, 0/1/2/3/4/5/6 | 721/1,584/1,522/1,361/812/494/155 | 260/591/537/464/288/166/51 | 461/993/985/897/524/328/104 | 0.084 |
| Treatment, SR/RFA/PEI/TACE/others/BSC | 1,734/2,243/79/1,587/423/583 | 563/1,075/46/372/73/228 | 1,171/1,168/33/1,215/350/355 | <0.001 |
| Observation period, years | 3.31 (3.11) | 3.2 (3.01) | 3.36 (3.17) | 0.038 |
Values for age, tumor size, and observation period are expressed as mean (SD). HCV, hepatitis C virus; HBV, hepatitis B virus; Alc, alcohol; nonBnonC, both negative for HBV and HCV; UK, unknown; ALBI grade, albumin-bilirubin grade; mALBI grade, modified ALBI grade; JIS, Japan Integrated Staging; TNM stage, tumor node metastasis according to the criteria of the Liver Cancer Study Group of Japan, 6th edition; ALBI-T, ALBI-TNM; mALBI-T, mALBI-TNM; SR, surgical resection; RFA, radiofrequency ablation; PEI, percutaneous ethanol injection therapy; TACE, transcatheter arterial chemoembolization; BSC, best supportive care.